New Test for Rare Immunodeficiency
Researchers at the University of Basel have developed a test to quickly and reliably diagnose a rare and severe immune defect, hepatic veno-occlusive disease with immunodeficiency. They reported on their findings in the Journal of Clinical Immunology.
Rare diseases are often only diagnosed very late, especially since in many cases, diagnostic tests are not available or are only available in a few laboratories. Hepatic Veno-occlusive disease with immunodeficiency is a clear example of this. It is an immunodeficiency caused by a mutation in the gene Sp110, and children suffering from it often die of severe infections or liver failure during the first year of life.
First described in 1976, this disease is still difficult to treat and is often fatal. It is also unclear what function the Sp110 gene actually has and why Sp110 protein deficiency leads to a severe immune defect and liver disease.
Rapid detection of missing Sp110 protein
One reason for the lack of progress in the treatment of this disease is that it had previously not been possible to detect the expression of the Sp110 protein in immune cells without significant effort. Mike Recher’s research group from the University of Basel’s Department of Biomedicine has now published a new, quick and easy-to-use test that shows the presence of the Sp110 protein in immune cells from the patient’s blood.
The detection is based on flow cytometry, a method in which the properties of individual cells are measured using laser light. The researchers were able to use the test to reliably determine patients with different mutations in the Sp110 gene in a matter of hours.
“We expect that this test will soon be used in laboratories to diagnose a Sp110 deficiency,” says Professor Recher. “The test will also help us quickly discover more about the biological function of Sp110.”
This article has been republished from materials provided by the University of Basel. Note: material may have been edited for length and content. For further information, please contact the cited source.
Marquardsen, F. A., Baldin, F., Wunderer, F., Al-Herz, W., Mikhael, R., Lefranc, G., . . . Recher, M. (2017). Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency. Journal of Clinical Immunology. doi:10.1007/s10875-017-0431-5
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018